Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2012

View Archived Issues

Abbott presents new serotonin 5-HT6 receptor modulators

Co-clinical study method identifies mutations limiting lung cancer treatment efficacy

Tyrosine-protein kinase SYK inhibitor has beneficial effects on asthma

Preliminary phase I results presented on AZD-2014

Olodaterol shows efficacy in asthma trials

Clinical data show long-term effects of lebrikizumab and the role of periostin

Novel GPR17 receptor modulators reported by Italian group

Theravance discloses novel candidate hepatitis C therapies

GlaxoSmithKline discovers new LDH-A inhibitors

Novel treatments for IBD prepared by Spanish team

Researchers at Marine Polymer Technologies patent new potential melanoma vaccines

Astellas and Drais partner on another IBS drug candidate

OTSA-101 receives E.U. orphan drug status

GE Healthcare and Affibody collaborate on HER2-specific PET imaging agent

Baxter and Chatham enter collaboration on hemophilia B gene therapy development

Takeda expands its position in gout market

First-in-human data presented on novel selective Notch pathway inhibitor

AFFiRiS launches first-ever clinical study of vaccine candidate for Parkinson's disease

Cleveland BioLabs reports survival results with CBLB-502

Emergent BioSolutions obtains BARDA funding for BioThrax

Evotec/Boehringer Ingelheim alliance reaches milestone

ThromboGenics and BioInvent to regain global rights to PlGF-directed mAb

Phase IIb data on anticoagulant lead to decision to stop its development

Genmab and Novartis enter bispecific antibody collaboration

Dainippon Sumitomo Pharma and Shionogi to copromote combination hypertension drug in Japan

Janssen files NDA for canagliflozin

Astellas and Ambit begin phase IIb quizartinib monotherapy study in relapsed/refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...